SCHEMBL4285064

SCHEMBL4285064

Nc1cccc(Nc2nccc(Oc3ccc4c(ccn4-c4ccccc4)c3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.46
CDK5 Q00535 1/20 0.45
RET P07949 1/20 0.43
FLT1 P17948 1/20 0.43
ABL1 P00519 2/20 0.42
BCR P11274 2/20 0.42
SRC P12931 2/20 0.42
PLK4 O00444 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
EGFR P00533 1/20 0.41
PRKACA P17612 1/20 0.41
PRKACG P22612 1/20 0.41
PRKACB P22694 1/20 0.41
MET P08581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293466 0.93 ABL1 (0.48) KDRCDK5RETFLT1ABL1
SCHEMBL4280981 0.93 ABL1 (0.48) KDRCDK5RETFLT1ABL1
SCHEMBL4279484 0.92 CDK5 (0.46) KDRCDK5RETFLT1ABL1
SCHEMBL4279410 0.92 MET (0.45) KDRCDK5RETFLT1ABL1
SCHEMBL4294118 0.91 KDR (0.52) KDRRETFLT1PLK4KDM4C
SCHEMBL4288235 0.91 CDK5 (0.45) KDRCDK5RETFLT1ABL1
SCHEMBL4287054 0.91 KDR (0.44) KDRCDK5RETFLT1ABL1
SCHEMBL4288896 0.91 CDK5 (0.46) KDRCDK5RETFLT1ABL1
SCHEMBL4279382 0.90 KDR (0.45) KDRCDK5RETFLT1ABL1
SCHEMBL4284798 0.89 CDK5 (0.46) KDRCDK5RETFLT1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 KDR 165/4885CDK5 113/4885RET 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.